GlassScriptPhysician profile
Saman Karl Jayasinghe
NPI 1306162672
$1,660.40
in general payments reported to CMS, 2019-2025
15 companies · $695 in 2025
The $695 reported for 2025 was more than what 83% of Public Health & General Preventive Medicine providers received nationally (typical 2025 total: $95.27).
See the full distribution for Public Health & General Preventive Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.65 · 2021: $20.38 · 2022: $53.49 · 2023: $406 · 2024: $461 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522 · Long Term Medical Supply Or Device Loan: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.92 |
| Long Term Medical Supply Or Device Loan | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $901.77 | 2023-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Lilly USA, LLC | $241.02 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $103.34 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $79.40 | 2023-2024 | Shingrix, Arexvy |
| Novo Nordisk INC | $62.18 | 2023-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $48.92 | 2023 | |
| Merck Sharp & Dohme LLC | $47.20 | 2022-2023 | Verquvo, Belsomra |
| Organon LLC | $42.95 | 2021-2022 | |
| Pfizer INC. | $26.09 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $24.65 | 2019 | |
| Biocryst US Sales Co., LLC | $18.49 | 2023 | Orladeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.66 | 2023 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.27 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $16.01 | 2024 | Airsupra |
| Horizon Therapeutics Plc | $15.45 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saman Jayasinghe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.